Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.
